Novavax (NASDAQ: NVAX) Reports Narrower 3Q Loss
Buffalo, New York 11/08/2009 12:15 AM GMT (TransWorldNews)
Drug developer Novavax Inc. (NASDAQ: NVAX) said its third-quarter loss narrowed slightly on lower expenses following staff cuts and other cost cutting, according to Associated Press.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
Novavax lost $7.5 million, or 8 cents per share, compared with a loss of $7.8 million, or 12 cents per share, during the same period a year prior. Revenue rose 3.6 percent to $201,000 from $194,000.
Analysts polled by Thomson Reuters expected a loss of 9 cents per share.
Operating costs and expenses fell 15 percent to $8.5 million.
The company is currently developing a pandemic and seasonal flu vaccine.
Shares of Novavax fell 14 cents, or 3.5 percent, to $3.89 in midday trading. The stock has traded between 52 cents and $7.79 over the last 52 weeks.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
staff@bestdamnpennystocks.com
www.bestdamnpennystocks.com
Email Article to a friend
|
View Profile
Visit Blogs
|
NEWS ALERTS
Receive alerts for
Best Damn Penny Stocks
to your inbox.
Sign up for TransWorldNews Alerts
TransWorldNews, Inc. and its affiliate sites disclaim all liability for information and content provided by clients and appearing within their news and press releases.
